UBS
http://www.ubs.com/UBS provides a range of financial services, including advisory services, underwriting, financing, market making, asset management, brokerage and retail banking on a global level. The Company consists of four divisions: Wealth Management, Asset Management, Investment Banking & Security and Swiss Retail & Corporate Banking. Wealth Management offers high net worth customers advice and investment services, Asset Management offers management solutions for most types of asset class to a range of clients, Investment Banking & Security provides securities, products and research in various areas equities and Swiss Retail & Corporate Banking offers banking and securities services for Swiss clients.
UBS Maintains a 'Neutral' on Alexion Pharmaceuticals (ALXN); Raising Price Target on FY2011 Guidance
-
UBS Downgrades Alexion Pharmaceuticals (ALXN) to Neutral
-
UBS Maintains a 'Buy' on Alexion Pharma (ALXN); Expect Greater Uptake of Soliris in aHUS
-
Notable Analyst Rating Changes 09/22: VVUS, BAX, ALXN, DLB Upgraded; ADBE, NOK, PMCS, SOHU Downgraded
-
UBS Maintains a 'Buy' on Alexion Pharma (ALXN); Raises PT on aHUS opportunity
-
David Moenning's Daily State of the Markets: 4/23
-
Notable Analyst Rating Changes 2/9: WYE, PFE, ADBE, CHK, GLW, BIG Upgraded; LEN, PAS, CVX, DOW Downgraded
-
David Moenning's Daily State of the Markets: 10/23
-
David Moenning’s Daily State of the Markets: 07/29
-
David Moenning's Daily State of the Markets: 2/14
-
UBS Initiates Coverage on Alexion Pharmaceuticals (ALXN) with a Buy
